Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis-Reference-Cited by-同舟云学术

Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis

Published:2020-12-24 Issue:1 Volume:81 Page:157-168
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Syed Yahiya Y.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-020-01437-2.pdf

Reference82 articles.

1. Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol. 2013. https://doi.org/10.4172/2155-9899.1000152.

2. Li Z, Richards S, Surks HK, et al. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol. 2018;194(3):295–314.

3. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–8.

4. Garnock-Jones KP. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis. Drugs. 2014;74(4):489–504.

5. European Medicines Agency. Lemtrada 12 mg concentrate for solution for infusion: EU summary of product charateristics. 2019. https://www.ema.europa.eu/. Accessed 12 Aug 2020.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biotechnology Advances in Disease Treatment;International Encyclopedia of Public Health;2025

2. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects;Pharmacological Reports;2024-08-23

3. Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study;Multiple Sclerosis Journal;2024-08

4. Transcriptome Analyses of Liver Sinusoidal Endothelial Cells Reveal a Consistent List of Candidate Genes Associated with Endothelial Dysfunction and the Fibrosis Progression;Current Issues in Molecular Biology;2024-07-25

5. Very late-onset membranous nephropathy secondary to alemtuzumab in a patient with multiple sclerosis;Neurology Perspectives;2024-07